Latanoprost Al

Latanoprost, the active ingredient in Latanoprost Al, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It treats open‑angle glaucoma and ocular hypertension by lowering intra‑ocular pressure in adult patients.

GNH USA supplies Latanoprost Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to help prevent optic‑nerve damage. Ocular hypertension: lowers eye pressure to decrease the risk of developing glaucoma. Pseudoexfoliative glaucoma: helps control pressure in eyes affected by pseudoexfoliation syndrome.

Latanoprost may cause ocular and peri‑ocular reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness (hyperemia) - Increased eyelash length and thickness - Darkening of the iris pigment - Eye irritation or foreign‑body sensation - Blurred vision shortly after instillation - Mild itching or burning on application

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Uveitis or intra‑ocular inflammation - Macular edema, especially in patients with risk factors - Paradoxical increase in intra‑ocular pressure - Corneal edema or endothelial changes

Before initiating therapy, consider the following safety measures.

Monitor intra‑ocular pressure: schedule regular pressure checks. Assess for ocular infections: avoid use if active conjunctivitis or keratitis is present. Avoid contact lenses: discontinue lens wear during treatment and for several hours after instillation. Caution in patients with a history of uveitis: watch for inflammatory signs. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use of other prostaglandin analogs: may increase local side‑effects. - Simultaneous use of systemic carbonic anhydrase inhibitors: additive IOP‑lowering effect requires monitoring.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may reduce latanoprost efficacy. - Beta‑blocker eye drops: additive pressure reduction may lead to excessive lowering. - Topical corticosteroids: may diminish the IOP‑lowering response.